Market Overview

Celgene Higher Off Positive Phase II Sunbeam Trial Of Oral Ozanimod

Related CELG
Dow 30 Stock Roundup: Boeing Bags Big Orders at Paris Air Show; Wal-Mart to Buy Bonobos
Benzinga's Option Alert Recap From June 21
Too Late To Catch Biotech Rally As Trump Fears Subside? (Investor's Business Daily)

Celgene Corporation (NASDAQ: CELG) shares are trading higher by $2.00 at $120.66 in Friday's session. The catalyst for the rally is a Phase II study of Oral Ozanimod with relapsing MS meeting its primary endpoint in reducing ARR, measured endpoints.

After a higher open, it had a brief retreat but found found support just under above Thursday's close ($118.66), only reaching $118.81 before continuing its move higher.

So far, the ensuing rally has cleared the pair of highs from Wednesday ($120.63) and Thursday ($120.77), reaching $120.90. If the rally continues, the next resistance daily resistance point comes in at its January 19 high of $121.59.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (CELG)

View Comments and Join the Discussion!